Expression and immunogenicity of the C-terminus of a major blood-stage surface protein of Plasmodium vivax, Pv200(19), secreted from Saccharomyces cerevisiae.
The carboxy-terminus of the major merozoite surface protein of Plasmodium has been shown to be the target of protective immunity in a number of non-vivax malaria parasite species. In an effort to develop a protective vaccine for Plasmodium vivax, the most prevalent form of human malaria, we expressed in Saccharomyces cerevisiae the 19-kDa a carboxy-terminus of Pv200 as a His6-tagged, secreted polypeptide. Five of seven H-2 congenic mouse strains elicited antibodies that recognized yeast produced PV200(19) by ELISA. The vaccine appears to be immunogenic and widely recognized, and to contain one or more helper T cell epitopes that may allow boosting with subsequent natural infections.
Kaslow
D C
DC
Malaria Vaccines Section, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892-0425, USA.
Kumar
S
S
D000595:Amino Acid Sequence; D000818:Animals; D000953:Antigens, Protozoan / Q000096:biosynthesis* / Q000276:immunology*; D000954:Antigens, Surface / Q000096:biosynthesis* / Q000276:immunology*; D005822:Genetic Vectors / Q000276:immunology / Q000378:metabolism; D010966:Plasmodium vivax / Q000254:growth & development / Q000276:immunology*; D012441:Saccharomyces cerevisiae / Q000235:genetics* / Q000276:immunology / Q000378:metabolism
D000953:Antigens, Protozoan; D000954:Antigens, Surface; C073018:Pv200 antigen, P vivax